Research
Molecular
The supramolecular GLP-1 receptor agonist (PA-GLP1) formulation achieved sustained serum concentrations for at least 40 days in a rat model of type 2 diabetes.
This formulation may provide a long-lasting treatment option for diabetes management.
StrongSupportsmedium confidence
In a rat model of type 2 diabetes, a single injection of the supramolecular PA-GLP1 formulation achieved sustained serum concentrations for at least 40 days.
Why this rating
Based on the use of a rat model to demonstrate sustained effects.
Source
Engineering Supramolecular Nanofiber Depots from a Glucagon-Like Peptide-1 Therapeutic
Weike Chen et al. · ACS Nano · 2024
otherCited 6×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →